Loading
A phase 2 trial of Gemcitabine in cervical cancer, run by Grit Biotechnology, now recruiting.
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06241781 by Grit Biotechnology, with 83 participants planned, started 2024-04-02 and due to reach its primary completion in 2027-01-31. Interventions recorded: GT101 injection and Gemcitabine injection.
Shares Grit Bio and the tag pipeline.
Shares Grit Bio and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.